Literature DB >> 21671865

Rational design and development of colon-specific prodrugs.

Suneela S Dhaneshwar1, Gaurav Vadnerkar.   

Abstract

Earlier colon was considered as a black-box, acting as a site for production and temporary storage of excreta and responsible for absorption of electrolytes and water. But, with the discovery of sulfasalazine as colon-specific prodrug, the promising and challenging issue of treating local pathologies was presented with colon as an organ of significance for target-specific delivery of drugs. The need and desirable attributes of colon-specific drug delivery systems have been well recognized, extensively explored and documented in the literature. The success of a colon-specific prodrug depends on its rational design and understanding the demands of the organ to be targeted and the delivery system to be developed. The present review mainly focuses on anatomy/physiology of colon, colonic microbiota, enzymatic set up of colon, pathophysiology of local diseases of colon, factors, obstacles and rationale for designing colon specific drug delivery system, various targets, potential drug candidates and novel colon-targeting carriers along with varied linkages that could be explored, merits and demerits of this design and recent trends in this field. Brief review of methodologies for characterization and in vitro/in vivo release studies is presented. The available animal models with quantifying parameters for evaluating colon-targeting potential and effectiveness of the colon-specific prodrugs for inflammatory bowel disease is also included in this review.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671865     DOI: 10.2174/156802611797183249

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  7 in total

Review 1.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

2.  Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats.

Authors:  Shakuntala Santosh Chopade; Suneela Sunil Dhaneshwar
Journal:  World J Gastroenterol       Date:  2018-03-14       Impact factor: 5.742

3.  Synthesis of a novel PEGylated colon-specific azo-based 4- aminosalicylic acid prodrug.

Authors:  Fatemeh Sadeghi; Atie Eidizade; Farinaz Saremnejad; Farzin Hadizadeh; Elham Khodaverdi; Abbas Akhgari
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

4.  Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.

Authors:  Ajinkya Sarkate; Suneela S Dhaneshwar
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

5.  Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors.

Authors:  Dawn M George; Raymond J Huntley; Kevin Cusack; David B Duignan; Michael Hoemann; Jacqueline Loud; Regina Mario; Terry Melim; Kelly Mullen; Gagandeep Somal; Lu Wang; Jeremy J Edmunds
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

6.  Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling.

Authors:  Wai-Hung Leung; Jing-Wen Shih; Jian-Syun Chen; Ntlotlang Mokgautsi; Po-Li Wei; Yan-Jiun Huang
Journal:  Biomedicines       Date:  2022-02-04

Review 7.  Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.

Authors:  Amjad M Qandil
Journal:  Int J Mol Sci       Date:  2012-12-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.